KUALA LUMPUR, March 3 -- Takeda Pharmaceutical Company Limited (Takeda) has completed its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets to Acino for a total value in excess of US$200 million (US$1 = RM4.20).
The transaction includes approximately 30 select prescription pharmaceutical and OTC products in a number of Near East, Middle East and Africa countries within Takeda’s Growth and Emerging Markets Business Unit.
These products will continue to be made available by Takeda in other parts of the world.
Close to 270 employees, primarily sales and marketing professionals supporting the portfolio, are also transitioning to Acino.
The parties also entered into multi-year manufacturing and supply agreements, under which Takeda will continue to manufacture the products on behalf of Acino.
The Japan-based Takeda has now announced several transactions as part of its efforts to deleverage and focus on its five key business areas.
In addition to the Acino transaction, Takeda completed the sale of Xiidra® to Novartis for up to US$5.3 billion, announced the sale of TachoSil® to Ethicon for US$400 million and announced its sale of non-core assets spanning the Russia-CIS region.
Takeda intends to use proceeds from these divestitures to reduce debt and continue to deleverage towards its target of 2x net debt/adjusted EBITDA within March 2022 - March 2024.
-- BERNAMA
No comments:
Post a Comment